Engineering ionizable lipids for rapid biodegradation balances mRNA vaccine efficacy and tolerability

Author:

Couture-Senécal JulienORCID,Tilstra GraysonORCID,Khan Omar F.ORCID

Abstract

AbstractThe optimization of lipid nanoparticles (LNPs) has played a key role in enhancing the efficacy of mRNA vaccines, yet challenges with LNP tolerability remain. The ionizable lipid component within LNPs is critical to the efficient delivery of mRNA. Ionizable lipids can also trigger innate immune activation, which is beneficial for vaccine efficacy but may contribute to adverse inflammatory reactions. Engineering ionizable lipids for rapid biodegradation is a promising, yet underexplored, strategy to dampen inflammation. Here, we report the rational design and optimization of biodegradable ionizable lipids for intramuscular mRNA vaccines in mice. We show that in vivo biodegradability is enhanced by controlling lipid hydrolysis kinetics and that protein output is maximized by tuning the LNP apparent pKa. In an influenza vaccine model, the lead lipid (δO3) generates equivalent neutralizing antibodies and stronger antigen-specific T cell responses compared to a benchmark lipid (SM-102) used in approved mRNA vaccines. Furthermore, by comparing ionizable lipid analogs with similar potency but opposing biodegradation kinetics, we find that faster lipid clearance from tissues coincides with a lower inflammatory response while preserving strong vaccine immunogenicity. These findings demonstrate that fast-degrading ionizable lipids can balance the efficacy and tolerability of mRNA vaccines, with implications for addressing side effects and patient acceptance of new vaccine applications.

Publisher

Cold Spring Harbor Laboratory

Reference45 articles.

1. Messenger RNA-Based Vaccines Against Infectious Diseases

2. Evolution of the market for mRNA technology;Nat. Rev. Drug Discov,2021

3. The engineering challenges and opportunities when designing potent ionizable materials for the delivery of ribonucleic acids;Expert Opin. Drug Deliv,2022

4. Pfizer. COMIRNATY [package insert]. U.S. Food and Drug Administration website.https://www.fda.gov/media/151707/download?attachment. Revised October 2023.

5. Moderna. SPIKEVAX [package insert]. U.S. Food and Drug Administration website.https://www.fda.gov/media/155675/download. Revised April 2024.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3